These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 8314382)
1. Heterogeneity of chemosensitivity in human breast carcinoma: use of an adenosine triphosphate (ATP) chemiluminescence assay. Hunter EM; Sutherland LA; Cree IA; Dewar JA; Preece PE; Wood RA; Linder D; Andreotti PE Eur J Surg Oncol; 1993 Jun; 19(3):242-9. PubMed ID: 8314382 [TBL] [Abstract][Full Text] [Related]
2. [-Chemosensitivity testing in gynecologic oncology. Experiences with an ATP bioluminescence assay-]. Kurbacher CM; Mallmann P; Kurbacher JA; Hübner H; Krebs D Geburtshilfe Frauenheilkd; 1996 Feb; 56(2):70-8. PubMed ID: 8647362 [TBL] [Abstract][Full Text] [Related]
3. In vitro chemosensitivity in breast cancer using ATP-tumor chemosensitivity assay. Qi CJ; Ning YL; Zhu YL; Min HY; Ye H; Qian KQ Arch Pharm Res; 2009 Dec; 32(12):1737-42. PubMed ID: 20162402 [TBL] [Abstract][Full Text] [Related]
4. [Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer]. Tian HM; Shi XY; Fu J; Chao DY; Zhang K; Wu LY; Wang JW; Zhang W Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):296-8. PubMed ID: 15996325 [TBL] [Abstract][Full Text] [Related]
5. Anticancer chemosensitivity profiles of human breast cancer cells assessed by in vitro DNA synthesis inhibition assay. Nio Y; Tamura K; Kan N; Inamoto T; Ohgaki K; Kodama H Anticancer Res; 2000; 20(2B):1237-44. PubMed ID: 10810427 [TBL] [Abstract][Full Text] [Related]
7. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Andreotti PE; Cree IA; Kurbacher CM; Hartmann DM; Linder D; Harel G; Gleiberman I; Caruso PA; Ricks SH; Untch M Cancer Res; 1995 Nov; 55(22):5276-82. PubMed ID: 7585588 [TBL] [Abstract][Full Text] [Related]
8. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer. O'Meara AT; Sevin BU Gynecol Oncol; 2001 Nov; 83(2):334-42. PubMed ID: 11606094 [TBL] [Abstract][Full Text] [Related]
9. [Value of the adenosine triphosphate chemosensitivity assay for pre-therapeutic determination of the chemosensitivity of breast cancer cells in cell culture]. Köchli OR; Sevin BU; Schär G; Haller U Geburtshilfe Frauenheilkd; 1995 Jan; 55(1):7-16. PubMed ID: 7705600 [TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy for breast cancer determined by chemosensitivity assay achieves better tumor response. Lau GI; Loo WT; Chow LW Biomed Pharmacother; 2007 Oct; 61(9):562-5. PubMed ID: 17913448 [TBL] [Abstract][Full Text] [Related]
12. Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer. Moon YW; Choi SH; Kim YT; Sohn JH; Chang J; Kim SK; Park MS; Chung KY; Lee HJ; Kim JH Cancer; 2007 May; 109(9):1829-35. PubMed ID: 17366594 [TBL] [Abstract][Full Text] [Related]
13. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475 [TBL] [Abstract][Full Text] [Related]
14. [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients]. Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J Cancer Radiother; 2004 Jun; 8(3):155-67. PubMed ID: 15217583 [TBL] [Abstract][Full Text] [Related]
15. Potential use of the adenosine triphosphate cell viability assay in endometrial cancer. Tam KF; Ng TY; Tsang PC; Li CF; Ngan HY J Soc Gynecol Investig; 2006 Oct; 13(7):518-22. PubMed ID: 16979354 [TBL] [Abstract][Full Text] [Related]
16. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer. Cree IA; Kurbacher CM; Lamont A; Hindley AC; Love S; Anticancer Drugs; 2007 Oct; 18(9):1093-101. PubMed ID: 17704660 [TBL] [Abstract][Full Text] [Related]
17. Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay. Tanino H; Oura S; Hoffman RM; Kubota T; Furukawa T; Arimoto J; Yoshimasu T; Hirai I; Bessho T; Suzuma T; Sakurai T; Naito Y Anticancer Res; 2001; 21(6A):4083-6. PubMed ID: 11911296 [TBL] [Abstract][Full Text] [Related]
18. [Comparison of the cytostatic effect of epirubicin and mitoxantrone on native breast carcinoma cells using the ATP tumor chemosensitivity assay]. Kurbacher CM; Brenne U; Kurbacher JA; Mallmann P; Krebs D Zentralbl Gynakol; 1996; 118(5):271-8. PubMed ID: 8701623 [TBL] [Abstract][Full Text] [Related]
19. [The evaluation of adenosine triphosphate bioluminescence assay for chemosensitivity testing of ovarian cancer cell line]. Shi W; Gu M; Liang L Zhonghua Fu Chan Ke Za Zhi; 1996 Feb; 31(2):79-82. PubMed ID: 8758798 [TBL] [Abstract][Full Text] [Related]
20. Chemosensitivity and chemoresistance testing in ovarian cancer. Cree IA Curr Opin Obstet Gynecol; 2009 Feb; 21(1):39-43. PubMed ID: 19125002 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]